Spyre reports positive Phase 2 data for SPY002 in ulcerative colitis
Spyre Therapeutics announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial for SPY002 in ulcerative colitis patients. The therapy met its primary endpoint with a significant reduction in RHI score and showed a consistent safety profile.
*this image is generated using AI for illustrative purposes only.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY002, a potential best-in-class anti-TL1A therapy for moderately-to-severely active ulcerative colitis (UC). The treatment met its primary endpoint with a statistically significant reduction of 10.7 points (p<0.0001) from baseline at Week 12 in Robart's Histopathology Index (RHI) score, demonstrating a consistent safety profile. These results mark a significant step forward for the clinical-stage biotechnology company focused on advancing immunology treatments.
The Phase 2 SKYLINE trial evaluated SPY002 over a 12-week induction period. Spyre Therapeutics reported that the therapy was well tolerated, with safety data aligning with expectations. The company aims to deliver more complete disease control, greater durability, and a simpler treatment experience for patients through its next-generation therapies.
Key Trial Details
| Parameter | Details |
|---|---|
| Trial Name | SKYLINE |
| Phase | Phase 2 |
| Treatment | SPY002 |
| Indication | Moderately-to-severely active ulcerative colitis |
| Induction Period | 12 weeks |
| Primary Endpoint | Met |
| Safety Profile | Consistent, well tolerated |
SPY002 is being investigated as a potential best-in-class anti-TL1A treatment. The positive results from Part A of the trial support its continued development for ulcerative colitis, a chronic inflammatory bowel disease. Spyre Therapeutics is committed to developing therapies that elevate the standard in immunology by addressing unmet needs in chronic inflammatory conditions through innovative treatment approaches.
What are the next steps for SPY002 following the positive Part A data, and when will Part B of the SKYLINE trial commence?
How might these results influence Spyre Therapeutics' partnerships or collaborations with larger pharmaceutical companies?
What competitive advantages does SPY002 have over other anti-TL1A therapies currently in development for ulcerative colitis?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
